Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to set category-based product coverage and apply deferred price cuts for the price maintenance premium (PMP) for the first time in…
To read the full story
Related Article
- MHLW Official Reveals Rationales Behind Off-Year Decision, Says PMP Return Is Reasonable
January 8, 2025
- Japan to Set Up Fund to Spur Generic Shakeup; CEA, Market Expansion Re-Pricing on Agenda
December 26, 2024
- PhRMA/EFPIA Slam Govt for Off-Year Revision as Broader Industry Deplores Decision
December 26, 2024
- Gist of FY2025 Drug Price Revision
December 26, 2024
- CEA Expansion, Higher Copay Likely to Be Included in Minister Budget Deal
December 24, 2024
- Three Ministers Agree on Off-Year Drug Price Revision in FY2025
December 20, 2024
- Japan Set to Settle Off-Year Debate with “x1.0” Threshold for PMP Meds/Generics, “x0.5” for LLPs
December 20, 2024
- (Update) Average NHI-Market Price Gap Narrows to 5.2% to Hit Record Low
December 4, 2024
REGULATORY
- MHLW Panel Calls for Careful Design of OTC-Like Drug Charge System
March 23, 2026
- Japan Hands Out Orphan Tags to Ianalumab, Bleximenib, and Lots More Drugs
March 23, 2026
- Ex-LDP Lawmaker, Pharmacist Jun Matsumoto Dies at 75
March 23, 2026
- LDP Project Team Flags Drug Pricing as Key to Investment
March 19, 2026
- Japan Sets Up Radiopharma Discovery Hub in Fukushima, Targets Rare Cancers
March 18, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…